Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | SCD | O00767 | 4/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 8/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850776 | 0.97 | KDM4C (0.46) | ROCK1SCDMRGPRX4GPR52KDM4C | |
| SCHEMBL1849782 | 0.93 | KDM4C (0.43) | ROCK1SCDMRGPRX4GPR52KDM4C | |
| SCHEMBL1856110 | 0.90 | KDM4C (0.51) | ROCK1SCDMRGPRX4GPR52KDM4C | |
| SCHEMBL3217369 | 0.90 | GPR52 (0.50) | ROCK1GPR52KDM4C | |
| SCHEMBL1853064 | 0.87 | KDM4C (0.48) | ROCK1MRGPRX4GPR52KDM4C | |
| SCHEMBL1856629 | 0.87 | GPR52 (0.56) | GPR52 | |
| SCHEMBL3210823 | 0.82 | GPR52 (0.61) | SCDMRGPRX4GPR52 | |
| SCHEMBL1851302 | 0.82 | KDM4E (0.46) | ROCK1KDM4CKDM5BKDM4EKDM6B | |
| SCHEMBL3198407 | 0.81 | KDM4E (0.45) | ROCK1KDM4CKDM5BKDM4EKDM6B | |
| SCHEMBL1852186 | 0.81 | GPR52 (0.56) | ROCK1SCDMRGPRX4GPR52KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | ROCK1 2151/4885SCD 3465/4885MRGPRX4 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.